Molecular Diagnostic for Infectious Diseases Market Size and Forecasts (2020-2030)
Molecular Diagnostic for Infectious Diseases Market Size and Forecasts (2020 – 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type (Point-of-Care Testing and Laboratory Testing), End User [Point-of-Care Testing (Human Testing and Vet Testing) and Laboratory Testing (Human Testing and Vet Testing)], Application [Point-of-Care Testing (Detection of Single Pathogen, Detection of Two or More Pathogens, Evaluation of Emerging Novel Infections, Surveillance and Early Detection of Biothreat Agents and Diseases-Related Biomarker, and Antimicrobial Resistance Profiling) and Laboratory Testing (Patient stratification, Drug Regimen Selection, Toxicity Avoidance, Therapeutic Monitoring, and Detection of Predisposition to Disease)], Disease Type [Point-of-Care Testing (Sepsis, Prosthetic Joint Infection, Endocarditis, STDs, Mononucleosis, Group A Streptococcus, and Others) and Laboratory Testing (Sepsis, Prosthetic Joint infection, Endocarditis, STDs, Chlamydia, Gastrointestinal Infection, Tuberculosis, H1N1 Virus, and Others)], Infection Type [Point-of-Care Testing (Bacteria, Viral, Fungi, and Others) and Laboratory Testing (Bacteria, Viral, Fungi, and Others)], and Geography (North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa)
$3,185 – $5,985
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
The growing demand for better treatment modalities has resulted in various product developments in the last few decades. A few of the examples of recent product developments in the molecular diagnostic for infectious diseases market are mentioned below.
• In April 2023, Bruker Introduced New Mycobacteria and Fungi IVD Solutions for MALDI Biotyper, and a Novel LiquidArray Gastrointestinal Syndromic Panel. With the introduction of new IVD workflows, kits, software and reference libraries for mycobacteria and fungi, the company further expand the applications of established MALDI Biotyper platform. This creates additional value for all current and future customers. The new LiquidArray Gastrointestinal is a next-generation syndromic panel with amazing pathogen coverage. It is ideal for laboratories which are interested in a broad screening approach to detect most pathogens in one run.
• In February 2023, Thermo Fisher Scientific launched PCR kits for infectious disease detection in India. Thermo Fisher Scientific announced that its Applied Biosystems TaqPath PCR kits for infectious diseases such as multi-drug-resistant tuberculosis (MTB MDR), M. tuberculosis complex (MTB), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and for genetic analysis (HLA B27) have received licensing rights by the Central Drugs Standard Control Organisation (CDSCO) and will be manufactured in India in association with Mylab Discovery Solutions.
• In December 2021, Roche launched the first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark. The launch of the cobas omni Utility Channel enables laboratory professionals the flexibility of running CE-IVD assays, as well as designing their own laboratory developed tests (LDTs). This new offering expands access to critical and robust diagnostic tools that enables healthcare providers to deliver high quality care to patients worldwide, including access to regions with the highest disease burdens.
Advancements in Molecular Diagnostics Technologies Provides New Opportunities for the Molecular Diagnostic for Infectious Diseases Market
Genetic and genomic research has led to the development of molecular diagnostic techniques that focus on nucleic acid detection, which provide new methods for detecting infectious diseases with a fast turnaround time. A molecular diagnostic technique detects multiple pathogens and analyzes drug-resistant genes of pathogens and pathogen homology analysis, making it an increasingly important tool for the early diagnosis of infectious diseases. Molecular diagnostic techniques and platforms are used in all areas of anatomic and clinical pathologies. DNA or RNA sequences associated with disease, including single nucleotide polymorphism, deletions, rearrangements, and insertions, can be detected via molecular diagnostic tests. Conventionally, CT scans, hematological tests, and reverse transcription-PCR (RT-PCR) were used for testing. Due to growing infectious diseases, the need for rapid, precise testing platforms surged to overcome the disadvantages of conventional testing. Computed tomography (CT), a cost-intensive procedure that may not be available in all hospitals, fails to detect viral infections and other diseases in asymptomatic patients. RT-PCR was also time-consuming and could not detect a low viral load during the early stages of infection. Reverse transcription loop-mediated isothermal amplification (RT-LAMP), microarray-based detection, aptamer-based diagnosis, SHERLOCK, SHERLOCKv2, FET Biosensors, cell-based potentiometric diagnosis, and molecular imprinting technology are a few examples of novel molecular diagnostics techniques developed for infectious disease diagnosis. In the last few years, the FDA reports have indicated that molecular testing, antigen-dependent testing, and serological testing have been approved due to the advancements. Collaborative efforts by scientific communities in different countries to manage infectious diseases and reduce the extent of mortality have benefited the overall molecular tools and diagnosis landscape, which will likely create significant opportunities for the molecular diagnostics for infectious diseases market in the future.
The molecular diagnostic for infectious diseases market is divided on the basis of type, disease type, infection type, application, and end user. Based on type, the market is classified into point-of-care testing and laboratory testing. The molecular diagnostic for infectious diseases market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The molecular diagnostic for infectious diseases market, by application, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of a single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarkers, and antimicrobial resistance profiling. Laboratory testing is further segmented into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The molecular diagnostic for infectious diseases market, by disease type, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of a sepsis, prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus (GAS), and others. Laboratory testing is further segmented into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The molecular diagnostic for infectious diseases market, by infection type, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Laboratory testing is further segmented into bacteria, viral, fungi, and others.
Based on geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the molecular diagnostic for infectious diseases market. The increasing acceptance of technologically advanced products, a rise in research and development activities, the presence of large healthcare businesses, and the growing use of molecular diagnostics kits for infectious disease diagnosis are among the key factors propelling the growth of the molecular diagnostics for infectious diseases market in North America. The molecular diagnostics for infectious diseases market growth in the US is primarily driven by the increasing prevalence of infectious disease, rising geriatric population, and multiple product launches by key players.
The National Institute of Health (NIH), Centers for Disease Control and Prevention (CDC), European Union, and United Nations International Children’s Emergency Fund (UNICEF) are a few key primary and secondary sources referred to while preparing the report on the molecular diagnostic for infectious diseases market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Publishing status: | |
| Geographical coverage: | |
| Year of Publication: |
Advancements in Molecular Diagnostics Technologies
Genetic and genomic research has led to the development of molecular diagnostic techniques that focus on nucleic acid detection, which provide new methods for detecting infectious diseases with a fast turnaround time. A molecular diagnostic technique detects multiple pathogens and analyzes drug-resistant genes of pathogens and pathogen homology analysis, making it an increasingly important tool for the early diagnosis of infectious diseases. Molecular diagnostic techniques and platforms are used in all areas of anatomic and clinical pathologies. DNA or RNA sequences associated with disease, including single nucleotide polymorphism, deletions, rearrangements, and insertions, can be detected via molecular diagnostic tests. Conventionally, CT scans, hematological tests, and reverse transcription-PCR (RT-PCR) were used for testing. Due to growing infectious diseases, the need for rapid, precise testing platforms surged to overcome the disadvantages of conventional testing. Computed tomography (CT), a cost-intensive procedure that may not be available in all hospitals, fails to detect viral infections and other diseases in asymptomatic patients. RT-PCR was also time-consuming and could not detect a low viral load during the early stages of infection. Reverse transcription loop-mediated isothermal amplification (RT-LAMP), microarray-based detection, aptamer-based diagnosis, SHERLOCK, SHERLOCKv2, FET Biosensors, cell-based potentiometric diagnosis, and molecular imprinting technology are a few examples of novel molecular diagnostics techniques developed for infectious disease diagnosis. In the last few years, the FDA reports have indicated that molecular testing, antigen-dependent testing, and serological testing have been approved due to the advancements. Collaborative efforts by scientific communities in different countries to manage infectious diseases and reduce the extent of mortality have benefited the overall molecular tools and diagnosis landscape, which will likely create significant opportunities for the molecular diagnostics for infectious diseases market in the future.
F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc, bioMerieux SA, Danaher Corp, Hologic Inc, Siemens Helathineers AG, Bruker Corp, Molzym GmbH & Co KG, and DiaSorin SpA are among the key players operating in the global molecular diagnostics for infectious diseases market.
Molecular Diagnostics Market, by Disease Type, 2022-2030 (%)
Source: the research team Analysis
The report segments the global molecular diagnostics market as follows:
Based on type, the molecular diagnostics for infectious disease market is segmented into point of care testing and laboratory testing. Based on end user, the molecular diagnostics market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The molecular diagnostic for infectious diseases market, by application, is segmented into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of a single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarkers, and antimicrobial resistance profiling. Laboratory testing is further segmented into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The molecular diagnostic for infectious diseases market, by disease type, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of a sepsis, prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus (GAS), and others. Laboratory testing is further segmented into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The molecular diagnostic for infectious diseases market, by infection type, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Laboratory testing is further segmented into bacteria, viral, fungi, and others. Geographically, the molecular diagnostics market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the molecular diagnostics for infectious disease market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the molecular diagnostics for infectious diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth market trends and outlook coupled with the factors driving the molecular diagnostics for infectious diseases market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
TABLE OF CONTENTS<div class="twocol"
LIST OF TABLES<div class="twocol"
LIST OF FIGURES
Figure 1. Molecular Diagnostic for Infectious Diseases Market Segmentation, By Geography
Figure 2. Global – PEST Analysis
Figure 3. Molecular Diagnostic for Infectious Diseases Market – Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 – 2030
Figure 6. Molecular Diagnostic for Infectious Diseases Market Revenue, Geography (US$ Mn), 2022 – 2030
Figure 7. Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
Figure 8. Point-of-Testing: Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Laboratory Testing: Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by End User, 2022 & 2030 (%)
Figure 11. Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
Figure 12. Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
Figure 13. Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
Figure 14. North America: Molecular Diagnostic for Infectious Diseases Market, by Key Country – Revenue (2022) (US$ Million)
Figure 15. North America Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 16. North America Molecular Diagnostic for Infectious Diseases Market, By Key Countries, 2022 and 2030 (%)
Figure 17. US Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 18. Canada Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. Mexico Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. Europe Molecular Diagnostic for Infectious Diseases Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 21. Europe Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Europe Molecular Diagnostic for Infectious Diseases Market, By Key Countries, 2022 and 2030 (%)
Figure 23. UK Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Germany Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. France Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Italy Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 27. Spain Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. Austria Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 29. Belgium Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 30. Luxembourg Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 31. The Netherlands Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 32. Rest of Europe Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 33. Asia Pacific Molecular Diagnostic for Infectious Diseases Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 34. Asia Pacific Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 35. Asia Pacific Molecular Diagnostic for Infectious Diseases Market, By Key Countries, 2022 and 2030 (%)
Figure 36. China Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 37. Japan Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 38. India Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 39. South Korea Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 40. Malaysia Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 41. Indonesia Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 42. Rest of Asia Pacific Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 43. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 44. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 45. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, By Key Countries, 2022 and 2030 (%)
Figure 46. Saudi Arabia Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 47. South Africa Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 48. UAE Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 49. Rest of Middle East & Africa Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 50. South & Central America Molecular Diagnostic for Infectious Diseases Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 51. South & Central America Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 52. South & Central America Molecular Diagnostic for Infectious Diseases Market, By Key Countries, 2022 and 2030 (%)
Figure 53. Brazil Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 54. Rest of South & Central America Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 55. Growth Strategies Done by the Companies in the Market, (%)
The List of Companies – Molecular Diagnostics for Infectious Diseases Market
o F. Hoffmann-La Roche Ltd
o Abbott
o Thermo Fisher Scientific Inc
o bioMérieux SA
o Danaher
o Digene and International Murex Technologies
o Hologic
o Siemens Healthcare Private Limited
o Bruker Corporation
o Molzym
You must be logged in to post a review.
Reviews
There are no reviews yet.